Rosemont Pharmaceuticals, a Leeds-based maker of oral liquid medicines owned by the private equity firm Inflexion, has agreed to buy Aytu BioPharma for $2.70 a share in cash.
What Rosemont is buying is a business in transition. Aytu’s ADHD products still supply most of its revenue, but they are shrinking under generic competition and a deliberate shift of sales effort away from them. EXXUA, the depression drug Aytu began selling in December 2025, is growing but still small. Aytu holds it under license, and a large share of every EXXUA dollar goes back to the licensor, Fabre-Kramer. Rosemont gets the U.S. commercial business that carries both.
What $2.70 buys
The merger agreement, signed November 16, provides for a tender offer followed by a second-step merger, in which any shares not tendered are acquired without a separate stockholder vote. The price is 51.7 percent above Aytu’s November 13 close and 41.1 percent above its 30-day volume-weighted average. Aytu’s directors, officers and stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management have agreed to tender. Both companies expect the deal to close in late December.
Aytu puts the price at about $56 million on a fully diluted basis, meaning shares plus the equity-linked securities that would convert. Common shares account for only about half of that. The filings reconcile the total:
- Common stock: 10.9 million shares outstanding on November 9, about $29.3 million at the offer price.
- Prefunded warrants: 8.8 million, effectively shares already paid for and exercisable at $0.0001 each, about $23.8 million.
- Other warrants: 2.2 million exercisable at $1.59 and 1.2 million at $2.32. Under the treasury stock method Aytu uses, they add about $2.9 million, which brings the total to Aytu’s figure.
The offer can close only if no more than 15 percent of Aytu’s warrants, measured by underlying shares, remain unexercised.
Debt and cash change the picture further. At September 30, Aytu held $25.5 million in cash against $10.7 million of term-loan principal and $6.0 million drawn on its revolving credit facility. Rosemont must pay off that debt at closing, along with early-termination fees. On those figures, cash exceeded funded debt by about $8.8 million, which would put the price paid for the operating business at roughly $47 million. That is a Behavioral Wire calculation, before fees, working-capital movements and a $3.0 million payment Aytu owes Fabre-Kramer in early 2027. Aytu’s net revenue for the fiscal year ended June 30, 2026, was $57.6 million.
The offer is also 80 percent above the $1.50 a share at which Aytu sold stock in June 2025, ahead of the EXXUA launch.
The business underneath
In the quarter ended September 30, compared with a year earlier:
- ADHD portfolio: $7.7 million, down from $13.2 million. Aytu attributes the drop to “reduced promotional emphasis as commercial resources shifted toward EXXUA” and to generic competition for Adzenys XR-ODT, a generic version of which launched in late 2025. For the full fiscal year, ADHD revenue fell 20 percent to $45.8 million. A separate patent case against Granules Pharmaceuticals over a proposed generic of the same product is scheduled for trial in January 2027.
- EXXUA: $4.9 million, against none a year earlier and $3.9 million in the June quarter. Prescriptions rose 32.5 percent from the June quarter to about 4,400, including roughly 1,650 in September. Aytu books revenue when product ships into the distribution channel, so revenue and prescriptions do not move in lockstep.
- Pediatric portfolio: $2.2 million, up from $0.7 million, which Aytu attributes to better payer mix and lower returns.
Total quarterly revenue rose 6.9 percent to $14.8 million, after a fiscal year in which it fell 13.3 percent. The launch has a cost: adjusted EBITDA was negative $2.6 million against negative $0.6 million a year earlier, and the net loss was $3.9 million. Aytu does not describe itself as financially distressed. In its quarterly report it said existing cash, operating cash flow and revolver availability would fund operations for at least the next 12 months.
What Rosemont gets in EXXUA
EXXUA (gepirone) is an approved, launched product. The FDA approved it for major depressive disorder in adults on September 22, 2023, under an application held by Fabre-Kramer. Aytu acquired exclusive U.S. commercialization rights in June 2025, made the drug available in mid-December 2025 and deployed its full sales force in late February 2026. Rosemont is buying Aytu’s position as licensee, with its obligations, not the drug itself.
Those obligations are substantial:
- Royalties: 28 percent of EXXUA net revenue, rising to 39 percent in any year net revenue exceeds $300 million. A lower schedule of 24.5 and 35.5 percent applies after a reduced-royalty trigger.
- Supply: Aytu also pays Fabre-Kramer a supply price of 3 percent of net revenue less its cost of goods sold, rising to 4 percent above $300 million.
- Milestones: Sales milestones ranging from $5 million to more than $100 million a year begin once annual net revenue passes $100 million. Above $1 billion, Fabre-Kramer receives 10 percent of net revenue.
- Second payment: $3.0 million is due in early calendar 2027, rising to $5.0 million only if first-year net revenue reaches $35 million. EXXUA’s cumulative net revenue through September 30 was $11.5 million.
The license can be terminated by either party if the drug is withdrawn for safety reasons, if the FDA materially restricts its indications, or if federal or state price controls would cause a substantial loss of sales. Aytu amortizes the rights over an estimated remaining life of 3.9 years, its own accounting judgment of their economic life. The merger agreement conditions the offer on all required third-party consents. Its schedules were not filed, so whether Fabre-Kramer’s consent is among them is not public.
At current scale, more than a quarter of each EXXUA dollar goes back to Fabre-Kramer before Aytu pays for sales and marketing. The upside Rosemont acquires is shared, and the sales milestones begin only at $100 million in annual net revenue, about five times EXXUA’s latest quarterly revenue annualized.
Rosemont’s route into the United States
Inflexion agreed in 2020 to acquire Rosemont from Perrigo and said it would support the business’s geographic expansion. Rosemont had reached the U.S. through distribution partners before buying Sabal Therapeutics, a Georgia distributor of liquid medicines, in July 2024, which it said gave it the ability to supply the U.S. market directly. In a February 2024 interview with the trade publication Generics Bulletin, its then chief executive, Howard Taylor, described U.S. commercial businesses as the company’s top acquisition priority. Aytu extends that strategy into branded CNS medicines. Rosemont’s announcement describes the deal as bringing “an established ADHD portfolio and an emerging Major Depressive Disorder (MDD) asset alongside a US commercial platform,” and chief executive Alok Sonig called it “an important step in Rosemont’s US growth strategy.” Aytu’s orally disintegrating ADHD tablets and its oral-suspension pediatric product also sit close to Rosemont’s swallowing-friendly formats, though neither company has cited that as a reason for the deal.
Rosemont declined to participate in Behavioral Wire’s reporting for this article. Its announcement does not rank the platform, the ADHD products and EXXUA by importance.
What the record establishes
Rosemont is acquiring U.S. CNS commercial capacity at a point when Aytu’s revenue mix is moving away from an ADHD franchise under generic pressure and toward a young depression product whose economics are shared heavily with its licensor. On Behavioral Wire’s calculation, the operating business is valued at about 0.8 times last fiscal year’s revenue, and the EXXUA launch has yet to reach the sales level at which its license terms begin to escalate.
Why Aytu’s board chose this moment to sell is a separate question. The solicitation statement Aytu files when the tender offer opens should set out the sale process, any competing approaches, the projections and the fairness analysis behind its recommendation.